This finding is in agreement with a prior study that reported that the TRAIL resistance of glioblastoma CSCs was due to the insufficient expression of the death receptors DR4 and DR5 and the inhibition of the CD95/Fas domain (45). The gene discussed is FAS; the disease is glioblastoma.